Immunosuppressive requirements for small bowel/liver transplantation.
McAlister
V
V
Department of Surgery, University Hospital, London, Ontario, Canada.
Grant
D
D
Wall
W
W
Roy
A
A
Ghent
C
C
Zhong
R
R
Duff
J
J
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004386:Duodenum / Q000637:transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007421:Intestine, Small / Q000637:transplantation*; D016031:Liver Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use; D013270:Stomach / Q000637:transplantation; D014184:Transplantation, Homologous / Q000276:immunology*
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D011241:Prednisone; D008775:Methylprednisolone